Forms of HIV can cross from chimps to humans
No one knows exactly how it happened. It may have entered through a cut or bite wound, the blood of a chimpanzee seeping into an exposed fingertip or forearm or foot.
But in the early 1900s, probably near a West African rainforest, it's thought that a hunter or vendor of bush meat - wild game that can include primates - acquired the first strain of a simian immunodeficiency virus that virologists consider the ancestor of HIV.
A new study led by the University of Nebraska-Lincoln has supported this hypothesis by reporting the first in vivo evidence that strains of chimpanzee-carried SIVs can infect human cells. They include the SIV ancestor of HIV-1 M - the strain responsible for the global HIV pandemic - and another ancestral strain of HIV found only among residents of Cameroon.
Yet the researchers further discovered that the SIV ancestors of two HIV strains not identified in humans also managed to invade human cells after multiple exposures in the lab.
"The question was whether SIV strains that have not been found in humans have the potential to cause another HIV-like infection," said senior author Qingsheng Li, associate professor of biological sciences and member of the Nebraska Center for Virology. "The answer is that, actually, they do. They get replicated at a very high level. It's surprising."
Li and his colleagues came to the conclusions after inoculating mice that were implanted with human tissues and stem cells, which stimulated the growth of other cells essential to the human immune system. To explore why humans have acquired certain HIV strains while avoiding others, the team injected low doses of the four SIV strains into separate groups of the mice.
The authors found that the inferred SIV forerunners of HIV-1 M and the Cameroon-specific strain required fewer opportunities to infect the mice than did the two SIV strains whose HIV descendants have not been found in humans.
According to Li, this may stem from the fact that the genetic makeup of the latter two strains differs more from HIV-1 M than does the Cameroon strain, which shares more genes with its pandemic cousin.
"Based on our experiments, we clearly see some differences between the strains," said Li, whose team collaborated with the Frederick National Laboratory for Cancer Research. "That implies that there might be differences in the likelihood of cross-species transmission when a person is exposed to one strain versus another."The team also found evidence for the long-suspected notion that SIV strains mutate upon entering cells to overcome human-specific barriers to infection. Within 14 weeks, the same viral gene in two different SIV strains - including the ancestor of HIV-1 M - regularly underwent mutations at two key positions on that gene.
Li and lead author Zhe Yuan, a doctoral student in biological sciences, said the recent outbreak of the Zika virus - which remained relatively quiet for decades following its 1947 discovery in a monkey - underscores the value of pre-emptively identifying viruses that can jump from animals to humans.
"The emergence and re-emergence of infectious diseases has become a constant threat to global health, social stability, safety and economic systems," Li said. "Bill Gates recently said that nuclear war is no longer the (biggest) threat to our safety; emerging infectious diseases are. That's probably true."
The experimental approach employed by the team could help assess the threat posed by additional SIVs and numerous other animal-carried viruses, Yuan said. This could prove especially vital given the dynamic nature of HIV and other zoonotic diseases, he said, many of which have caused new epidemics or even pandemics.
"I think this analysis of the disease is very important for public health," said Yuan, noting that a new group of HIV strains was discovered in 2009. "We want to explore this platform for evaluating new, emerging infectious diseases."
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
